LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry
Climent, Elisenda (Universitat Autònoma de Barcelona. Departament de Medicina)
Bea Sanz, Ana Maria (Hospital Universitario Miguel Servet (Saragossa))
Benaiges, David (Institut Hospital del Mar d'Investigacions Mèdiques)
Brea-Hernando, Ángel (Hospital San Pedro, Logroño)
Pintó, Xavier (Hospital Universitari de Bellvitge)
Suarez Tembra, Manuel (Hospital San Rafael, A Coruña)
Perea, Verónica (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Plana, Núria (Hospital Universitari Sant Joan de Reus (Tarragona))
Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Pedro-Botet, Juan (Universitat Autònoma de Barcelona. Departament de Medicina)

Fecha:	2022
Descripción:	8 pàg.
Resumen:	Purpose: Low-density lipoprotein (LDL) cholesterol reduction by statin therapy is dose-dependent, varies among different statins, and has wide inter-individual variability. The present study aimed to compare mean LDL cholesterol reduction and its variability achieved with different doses of the three statins most frequently used in monotherapy or combined with ezetimibe in a real clinical setting. Methods: Of 5620 cases with primary hypercholesterolemia on the Spanish Arteriosclerosis Society Registry, 1004 with non-familial hypercholesterolemia and complete information on drug therapy and lipid profile were included. Results: The lowest mean percentage LDL cholesterol reduction was observed with simvastatin 10 mg (32. 5 ± 18. 5%), while the highest mean percentage LDL reduction was obtained with rosuvastatin 40 mg (58. 7 ± 18. 8%). As to combined treatment, the lowest and highest mean percentage LDL cholesterol reductions were obtained with simvastatin 10 mg combined with ezetimibe (50. 6 ± 24. 6%) and rosuvastatin 40 mg combined with ezetimibe (71. 6 ± 11. 1%), respectively. Factors associated with a suboptimal response were male sex, lower age, body mass index, and baseline LDL cholesterol levels. Combined treatment was associated with less variability in LDL cholesterol reduction (OR 0. 603, p < 0. 001). Conclusion: In a real clinical setting, rosuvastatin was superior to the other statins in lowering LDL cholesterol, both as monotherapy or combined with ezetimibe. Factors associated with a suboptimal response in LDL cholesterol decline were male sex, age, body mass index, and baseline LDL cholesterol levels. Combined treatment was associated with less variability in LDL cholesterol improvement.
Derechos:	Tots els drets reservats.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió de l'autor
Materia:	Cardiovascular risk ; Ezetimibe ; LDL cholesterol ; Lipid-lowering treatment ; Statins
Publicado en:	Cardiovascular Drugs and Therapy, Vol. 36 Núm. 2 (2022) , p. 301-308, ISSN 1573-7241

PMID: 33555511

20 p, 189.2 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados